



# MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)

Tel: 011-27430249, 27138171

E-mail: info@mediorganics.in | CIN No: L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

November 18, 2024

To,  
**National Stock Exchange of India Limited**  
**Listing & Compliance Department**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G Block, Bandra-Kurla Complex, Bandra  
Mumbai - 400051, India.

Company Symbol : **MEDIORG**  
Company ISIN : **INE0PE401018**

Dear Sir/Madam,

**Subject: Media Release - "Medicamen Organics Reports 49% Total Revenue Increase in H1 FY25"**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copy of Media Release titled "**Medicamen Organics Reports 49% Total Revenue Increase in H1 FY25**".

The above information will also be available on the website of company at [www.medicamenorganics.com](http://www.medicamenorganics.com).

Kindly acknowledge and take the same on records.

Thanking You,

Yours faithfully,  
For **Medicamen Organics Limited**

Bal Kishan  
Gupta

Digitally signed by Bal  
Kishan Gupta  
Date: 2024.11.18  
19:09:05 +05'30'

**Bal Kishan Gupta**  
**Managing Director**  
**DIN: 00032772**

**Place: New Delhi**

**Encl.: As stated above**

## Works:

**Unit-1** : Plot No. 60, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P1ZJ

**Unit-2** : Plot No. 61, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P3ZH



## Medicamen Organics Reports 49% Total Revenue Increase In H1 FY25

Mumbai - 18<sup>th</sup> November, 2024 – Medicamen Organics Limited (MOL) (NSE- MEDIORG) one of the prominent players in the pharmaceutical sector, specializing in the development, manufacturing, and distribution of an extensive range of pharmaceutical dosage has announced its Unaudited H1 FY25 results

### Key Financial Highlights

Particular (In ₹ Lakhs)	H1 FY25	H1 FY24	YoY
Total Revenue	1,685.66	1,132.00	48.91%
EBITDA	277.44	240.44	15.39%
PAT	151.07	136.25	10.88%

Commenting on the Financial Performance, **Mr. Bal Kishan Gupta, Managing Director** said, " We are pleased to report significant growth in total income, EBITDA, and net profit for the first half of FY25. This reflects the increasing demand for our organic health solutions and the effectiveness of our operational strategies. Our net profit continues to show positive growth, reinforcing the strength of our business.

Looking ahead, we are confident in our future prospects. Our agility allows us to secure key partnerships with global healthcare leaders, while our robust product pipeline promises the development of more & more products as per market requirement. With low debt, strong financials, and an expanding global presence, we are poised for substantial growth. We are well-positioned to expand and grow in Exports sector through our own brands and we are committed to create lasting value for our investors."

### Key Operational Highlights

<b>Expanding Global Reach</b>	The Company has signed an MoU with Depot Pharmacy Yego Limited in Rwanda, enhancing its overseas presence and expanding access to quality healthcare products in East Africa.
<b>Strategic Partnership to Expand in French West Africa</b>	<p>Signed a Memorandum of Understanding with Mr. Vaibhav Kashinath Chaudhari and Mistycube Analytics to form <b>Grande Etoile Pharmaceuticals Ltd.</b></p> <ul style="list-style-type: none"><li>• <b>Objective:</b> Build a strong business in the FWA market through strong marketing.</li><li>• <b>Ownership:</b> MOL will hold a 51% stake in GEPL.</li><li>• <b>Investment:</b> Authorized capital of ₹5 crores.</li></ul>

- |  |   |
|--|---|
|  | <ul style="list-style-type: none"><li>• <b>Operations:</b> GEPL will register products in FWA (own brands).</li></ul> |
|--|---|

### About Medicamen Organics Limited:

Medicamen Organics Limited stands out as a prominent player in the pharmaceutical sector, specializing in the development, manufacturing, and distribution of an extensive range of pharmaceutical dosage forms. These include Tablets, Capsules, Oral Liquids, Ointments, Gels, Syrups, Suspensions, and Dry Powders. The company's diverse offerings serve both state and central government institutions as well as private entities, operating as a contract and third-party manufacturer in India & International markets.

The company has two WHO GMP-approved manufacturing facilities located in Haridwar, Uttarakhand, covering an area of 21,536 sq. ft. These facilities feature cutting-edge infrastructure and in-house testing laboratories. A team of skilled and experienced professionals supports a streamlined production process, maintaining consistent quality.

Focused on global expansion, Medicamen Organics has made significant strides in establishing a direct international presence. Operating under a proven B2B contract manufacturing model, the company's products are distributed not only throughout India but also in African, CIS, and Southeast Asian countries, including Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, the Philippines, Myanmar, Mozambique, Kyrgyzstan, and Kenya.

The company's core business model revolves around B2B contract manufacturing, partnering with third-party pharmaceutical companies to market and sell its products. Medicamen Organics also engages actively in government tenders, supplying products to government hospitals, departments, PSUs, and armed forces.

The Company got listed on NSE Emerge in June 28, 2024.

For FY24, the Company has reported Total Income of ₹ 2528.96 Lakhs, with EBITDA of ₹ 475.56 Lakhs & PAT of ₹ 262.43 Lakhs.

### Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

### For Further Information Please Contact Corporate Communication Advisor



**Kirin Advisors Private Limited**

Sunil Mudgal – Director

[sunil@kirinadvisors.com](mailto:sunil@kirinadvisors.com)

+91 98692 75849

[www.kirinadvisors.com](http://www.kirinadvisors.com)